Publications by authors named "S Dalmia"
Objective: Reduced IGF-1 signalling is an evolutionarily conserved mediator of longevity, yet the magnitude of this effect is substantially larger in organisms retaining a common insulin and IGF-1 receptor. Whether this reflects the failure to simultaneously reduce IGF-1 and insulin signalling in mammalian model systems remains unexplored, as is the associated impact on markers of healthy ageing. We set out to address these uncertainties.
View Article and Find Full Text PDFNovel treatments for immune thrombocytopenia: targeting platelet autoantibodies.
Expert Rev Hematol
September 2024
Article Synopsis
- Immune thrombocytopenia (ITP) is an autoimmune disorder leading to low platelet counts and increased bleeding risk, with autoantibodies targeting platelet glycoproteins causing their destruction.
- New treatments, such as Neonatal Fc receptor (FcRn) antagonists and Syk inhibitors, aim to reduce harmful autoantibodies and improve patient outcomes by interfering with their clearance and production.
- The review emphasizes the significance of understanding these pathogenic mechanisms and highlights the promise of targeted therapies in managing ITP, despite the challenge of detecting autoantibodies.
Background: Dyspnoea is common following surgical resection for non-small cell lung cancer (NSCLC). The effects range from reduced quality of life to impact on adjuvant therapy outcomes. Currently, dyspnoea beyond the immediate postoperative phase and risk factors are not well characterised.
View Article and Find Full Text PDFArticle Synopsis
- Pompe disease is caused by a lack of the enzyme acid alpha-glucosidase (GAA), with treatments including enzyme replacement therapies like alglucosidase alfa and avalglucosidase alfa, though not all treatments are approved yet.
- A study was conducted to evaluate the effects of these therapies on individuals with late-onset Pompe disease (LOPD) by analyzing randomised controlled trials (RCTs).
- Six trials involving 358 participants were reviewed, showing that after 78 weeks, alglucosidase alfa likely improves walking distance but lacks data on some important outcomes like respiratory support needs.*
Background: We investigated the association between preoperative quality of life and long-term survival in patients undergoing surgical resection for non-small cell lung cancer.
Methods: Retrospective analysis was conducted on 388 consecutive patients who completed the quality of life assessment through the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 and lung cancer specific module (LC13), before anatomic lung resection for non-small cell lung cancer (2014-2018). Survival distribution was estimated by the Kaplan-Meier method.